This article focuses on the interaction of histiocytosis-X and the immunotherapeutic agent, suppression. Studies with this and other agents have presented us with invaluable insights into the nature of histiocytosis-X.
No takes yet. Share an insight, caveat, or question.
Michael E. Osband (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: